Get the Stockscreener App
16.82
2.25%
0.37
After Hours:
16.82
Maze Therapeutics Inc stock is traded at $16.82, with a volume of 51,167.
It is up +2.25% in the last 24 hours and up +47.41% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$16.45
Open:
$16.49
24h Volume:
51,167
Relative Volume:
0.37
Market Cap:
$736.67M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.40%
1M Performance:
+47.41%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.14
$17.10
1-Week Range:
$15.17
$18.67
52-Week Range:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
16.82 | 720.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
What analysts say about Maze Therapeutics Inc. stockExceptional profit potential - PrintWeekIndia
Why Maze Therapeutics Inc. stock attracts strong analyst attentionPredictable High Return Trades - Newser
What makes Maze Therapeutics Inc. stock price move sharplyFree Stock Market Entry & Exit Signals - Newser
What institutions are buying Maze Therapeutics Inc. stock nowFree Trading Strategy Suggestions - jammulinksnews.com
What drives Maze Therapeutics Inc. stock priceExtraordinary performance - Autocar Professional
Maze Therapeutics Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating - Investing.com UK
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock - TipRanks
Is Maze Therapeutics Inc. a good long term investmentHigh-velocity gains - Autocar Professional
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th - Defense World
how maze therapeutics inc. stock performs during market volatilityDaily Trade Opportunity - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at Wedbush - Defense World
Q2 Earnings Estimate for Maze Therapeutics Issued By Wedbush - Defense World
Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $23.50 - Defense World
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Maze Therapeutics Showcases Precision Medicine Pipeline at Major Kidney and Biotech Investor Conferences - Stock Titan
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says - MarketScreener
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position - TipRanks
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):